NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Alveron Pharma

Alveron Pharma

Private
OssHealthcare & Life Scienceshttps://www.alveron.com/

Last Round

Seed

Dec 6, 2024

Total Funding Raised

$17.08M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Alveron Pharma is a biotechnology company developing a unique coagulation platform technology with the world's first cyclodextrin-based anticoagulant reversal drug.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

intracranial hemorrhageICHreversal agentanticoagulant reversalcyclodextrin drugprocoagulantblood thinner reversalneurocritical carestroke treatmentclinical-stage biotechhematoma expansionsmall-molecule drugemergency medicinebleeding complication

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Alveron Pharma Comparables

Compare Alveron Pharma with similar companies based on industry and business-model similarity.

Alveron Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Pinwheel Therapeutics
90%
VarmX
89%
Bioxodes
82%

Alveron Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedDec 6, 2024
DebtOct 7, 2021
Series A ExtensionOct 7, 2021
Series AMay 16, 2019

Key People

Founding team and executive leadership

Alex Zwiers

Co-founder CDO

Founding Team

Stephan Peters

Founder & Chief Scientific Officer

Founding Team

Ben Nichols

CEO

Executive Team

Alveron Pharma Investors

Notable investors and investment history

Alveron Pharma investors
InvestorRounds
Waterman VenturesSeed, Series A, Series A Extension
Thuja CapitalSeed, Series A Extension, Series A
Waterman VenturesSeed, Series A
Oost NLSeed, Series A, Series A Extension
East Netherlands Development Agency (Oost NL)Seed, Series A
Broadview VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 18, 2026

    Monthly visitors grew 104% MoM, reaching 1.2K.

  • Dec 6, 2024

    $5.28M round led by Broadview Ventures

Alveron Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Alveron Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Alveron Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersOss
Employee Range5
Year Founded2019
Last FundingDec 6, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.